Top

Journal of Clinical Immunology

Published in:

01-05-2021 | Fibrinolytic Therapy | Letter to Editor

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

Authors: T. M. Ayodele Adesanya, Courtney M. Campbell, Lijun Cheng, Princess U. Ogbogu, Rami Kahwash

Published in: Journal of Clinical Immunology | Issue 4/2021

Excerpt

To the Editor: …

Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020;141:1739–41. https://doi.org/10.1161/CIRCULATIONAHA.120.047419.CrossRefPubMed

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–4. https://doi.org/10.1038/s41577-020-0320-7.CrossRefPubMed

Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. https://doi.org/10.1038/s41577-020-0311-8.CrossRefPubMed

Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. 2001;194(11):1609–16. https://doi.org/10.1084/jem.194.11.1609.CrossRefPubMedPubMedCentral

Panagiotou A, Trendelenburg M, Osthoff M. The lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front Immunol. 2018;9:1151. https://doi.org/10.3389/fimmu.2018.01151.CrossRefPubMedPubMedCentral

Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136–48. https://doi.org/10.1056/NEJMra1808012.CrossRefPubMed

Cotiguala L, Coover K, Bewtra A, Malesker M. Advances in the pharmacotherapy of hereditary angioedema. US Pharmacist. 2015;40(10):HS17–21.

Batarseh E, Kersten BP, Pinelo AC, Nadler JN, Schwartz SA. Angioedema in African Americans patients hospitalized for COVID-19. Am J Respir Crit Care Med. 2020;202:1581–4. https://doi.org/10.1164/rccm.202006-2223LE.CrossRefPubMedPubMedCentral

Roche J, Roche R. An open letter to the scientific community on the possible role of dysregulated bradykinin signaling in COVID-19 respiratory complications. 2020.

10.

Tolouian R, Vahed S, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Inj Prev. 2020;9(2):e19.CrossRef

11.

van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JWM, de Mast Q, Brüggemann RJ, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020;9:e57555. https://doi.org/10.7554/eLife.57555.CrossRefPubMedPubMedCentral

12.

Urwyler P, Moser S, Charitos P, Heijnen I, Rudin M, Sommer G, et al. Treatment of COVID-19 with Conestat Alfa, a regulator of the complement, contact activation and kallikrein-kinin system. Front Immunol. 2020;11:2072. https://doi.org/10.3389/fimmu.2020.02072.CrossRefPubMedPubMedCentral

13.

van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3(8):e2017708. https://doi.org/10.1001/jamanetworkopen.2020.17708.CrossRefPubMedPubMedCentral

14.

I-SPY COVID-19 TRIAL: an adaptive platform trial for critically Ill patients. https://clinicaltrials.gov/show/NCT04488081.

15.

Lanadelumab for treatment of COVID-19 disease. https://clinicaltrials.gov/show/NCT04422509.

16.

Prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19. https://clinicaltrials.gov/show/NCT04530136.

17.

Campbell CM. The opening salvo of anti-complement therapy against COVID-19. Lancet Rheumatol. 2020;2:e729–30. https://doi.org/10.1016/S2665-9913(20)30353-2.CrossRefPubMedPubMedCentral

18.

Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7(10):e1002331. https://doi.org/10.1371/journal.ppat.1002331.CrossRefPubMedPubMedCentral

19.

Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, et al. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses. 2020;12:4. https://doi.org/10.3390/v12040360.CrossRef

20.

McDowall MD, Scott MS, Barton GJ. PIPs: human protein-protein interaction prediction database. Nucleic Acids Res. 2009;37(Database issue):D651–6. https://doi.org/10.1093/nar/gkn870.CrossRefPubMed

21.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

22.

Carnivali G. Analyzing characteristics of the genetic network generated by genes linked to COVID-19. InterAm J Med Health. 2020;3.

23.

Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59–72.e15. https://doi.org/10.1016/j.cell.2020.05.032.CrossRefPubMedPubMedCentral

24.

Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609–15. https://doi.org/10.1038/s41591-020-1021-2.CrossRefPubMedPubMedCentral

25.

Caccia S, Suffritti C, Carzaniga T, Berardelli R, Berra S, Martorana V, et al. Intermittent C1-inhibitor deficiency associated with recessive inheritance: functional and structural insight. Sci Rep. 2018;8(1):977. https://doi.org/10.1038/s41598-017-16667-w.CrossRefPubMedPubMedCentral

26.

Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91–112.PubMed

27.

Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185–95. https://doi.org/10.1002/path.4454.CrossRefPubMed

28.

Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. Master regulator analysis of the SARS-CoV-2/human interactome. J Clin Med. 2020;9:4. https://doi.org/10.3390/jcm9040982.CrossRef

29.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26:842–4. https://doi.org/10.1038/s41591-020-0901-9.CrossRefPubMed

30.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70. https://doi.org/10.1080/22221751.2020.1747363.CrossRefPubMedPubMedCentral

31.

Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27:883–890.e2. https://doi.org/10.1016/j.chom.2020.04.017.CrossRefPubMedPubMedCentral

32.

Yan Q, Li P, Ye X, Huang X, Mo X, Wang Q et al. Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers. medRxiv. 2020:2020.05.05.20091355. doi:https://doi.org/10.1101/2020.05.05.20091355.

33.

Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–21. https://doi.org/10.1001/jama.2018.16773.CrossRefPubMedPubMedCentral

34.

Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014;35(6):444–53. https://doi.org/10.2500/aap.2014.35.3799.CrossRefPubMed

35.

Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med. 2017;377(1):52–61. https://doi.org/10.1056/NEJMoa1615887.CrossRefPubMedPubMedCentral

Title: C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19
Authors: T. M. Ayodele Adesanya
Courtney M. Campbell
Lijun Cheng
Princess U. Ogbogu
Rami Kahwash
Publication date: 01-05-2021
Publisher: Springer US
Keywords: Fibrinolytic Therapy
Severe Acute Respiratory Syndrome Coronavirus
COVID-19
Hereditary Angioedema
Hereditary Angioedema
Published in: Journal of Clinical Immunology / Issue 4/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-021-00972-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2021

The Impact of the SARS-CoV-2 Pandemic in PID Patients Receiving Ig Replacement Therapy

Infectious Complications Predict Premature CD8+ T-cell Senescence in CD40 Ligand-Deficient Patients

Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19

Successful Haploidentical Transplant Using Post-Transplant Cyclophosphamide in a Child with Chronic Granulomatous Disease—First Report from the Indian Subcontinent

Novel ADA2 Compound Heterozygous Mutations Resulting in Deficiency of Adenosine Deaminase 2 in a Pair of Siblings

Correction to: Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page